Adherium has announced that AstraZeneca will use Adherium’s SmartTouch Symbicort device in an upcoming 12-month clinical study of adherence in patients with COPD that is expected to enroll almost 400 US COPD patients. In July 2015, Adherium announced a deal to supply SmartInhaler technology for AstraZeneca's asthma and COPD patient support programs. According to … [Read more...] about Adherium SmartInhaler technology used in new AstraZeneca study
News
Consort reports growth for both Bespak and Aesica
In its annual report for the fiscal year ended 30 April 2016, Consort Medical reports that its subsidiary Bespak experienced revenue growth of almost 11%, and CDMO Aesica, which Consort acquired in November 2014, experienced "significant growth" and "encouraging EBIT margin growth." Overall revenue for Consort was up 50.4% to £276.9 million. Bespak's MDI growth was … [Read more...] about Consort reports growth for both Bespak and Aesica
Hovione breaks ground on expansion of US facility
Hovione has announced that the official groundbreaking for the expansion of its facility in New Jersey took place on June 8, 2016. The expansion will double the capacity of the facility by adding 30,600 sq ft, a new commercial spray drying unit, and approximately 60 new employees. The company announced plans for the expansion in September 2015. The existing 24,000 … [Read more...] about Hovione breaks ground on expansion of US facility
Nephron Pharmaceuticals launches generic budesonide inhalation suspension
US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex's generic budesonide inhalation suspension, a generic version of AstraZeneca's Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture, market, and distribute 0.5mg/2mL and 0.25mg/2mL dosage forms. The company's other … [Read more...] about Nephron Pharmaceuticals launches generic budesonide inhalation suspension
Iconovo signs licensing and development deal with Amneal Pharmaceuticals
Swedish DPI company Iconovo has announced a licensing and development deal with generics manufacturer Amneal Pharmaceuticals for a generic dry powder asthma/COPD therapy delivered by Iconovo's ICOres multidose DPI. According to the company, the deal includes an undisclosed upfront payment and "milestone payments in the mid-single digit Euro millions range." Iconovo … [Read more...] about Iconovo signs licensing and development deal with Amneal Pharmaceuticals
MannKind partners with JDRF on pediatric use of Afrezza
MannKind Corporation has announced that it signed an agreement with JDRF (formerly the Juvenile Diabetes Research Foundation) to collaborate on research focused on the use of Afrezza inhaled insulin in pediatric diabetes patients. JDRF is the largest non-profit funder of type 1 diabetes research in the world, according to the organization. The FDA approved … [Read more...] about MannKind partners with JDRF on pediatric use of Afrezza
Phillips-Medisize Acquires Medicom Innovation Partner
Device developer and manufacturer Phillips-Medisize has acquired Danish device company Medicom Innovation Partner (formerly Bang & Olufsen Medicom) for an undisclosed amount. The company said that, "The addition of Medicom’s capabilities expands Phillips-Medisize’s end-to-end injectable and inhalation device innovation service solutions for biopharma customers, … [Read more...] about Phillips-Medisize Acquires Medicom Innovation Partner
Acorda presents data from Phase 1 study of CVT-427 inhaled zolmitriptan
Acorda Therapeutics will present data from a Phase 1 study of its CVT-427 zolmitriptan DPI at the Annual Scientific Meeting of the American Headache Society, the company has announced. According to the company, the data show that the bioavailability of CVT-427 exceeded that of oral and intranasal zolmitriptan with lower variability in plasma concentrations. Acorda, … [Read more...] about Acorda presents data from Phase 1 study of CVT-427 inhaled zolmitriptan
Insmed withdraws MAA for Arikayce for nontuberculous mycobacteria (NTM)
Insmed has announced the withdrawal of its marketing authorization application for Arikayce inhaled liposomal amikacin for the treatment of nontuberculous mycobacteria (NTM) lung disease. The MAA was submitted to the European Medicines Agency in 2014, prior to the beginning of a Phase 3 study. According to the company, the Committee for Medicinal Products for … [Read more...] about Insmed withdraws MAA for Arikayce for nontuberculous mycobacteria (NTM)
Chiesi reports positive preliminary results from pivotal studies of triple combination MDI
Chiesi says that it is on track with planned regulatory submissions in the EU for its ICS/LAMA/LABA MDI for the treatment of COPD by the end of 2016 after successful completion of two 12-month Phase 3 studies. According to the company, preliminary results from the studies of the extrafine beclamethasone/formoterol/glycopyrronium combination therapy in more than 4,000 … [Read more...] about Chiesi reports positive preliminary results from pivotal studies of triple combination MDI